Infusion site adverse events in breast cancer patients receiving highly emetic chemotherapy with prophylactic anti-emetic treatment with aprepitant and fosaprepitant: A retrospective comparison-Reference-Cited by-同舟云学术

Infusion site adverse events in breast cancer patients receiving highly emetic chemotherapy with prophylactic anti-emetic treatment with aprepitant and fosaprepitant: A retrospective comparison

Published:2016-02-05 Issue:4 Volume:4 Page:603-606
ISSN:2049-9450
Container-title:Molecular and Clinical Oncology
language:en
Short-container-title:

Author:

TSUDA TAKASHI,KYOMORI CHISATO,MIZUKAMI TAKURO,TANIYAMA TOMOKO,IZAWA NAOKI,HORIE YOSHIKI,HIRAKAWA MAMI,OGURA TAKASHI,NAKAJIMA TAKAKO EGUCHI,TSUGAWA KOICHIRO,BOKU NARIKAZU

Publisher

Spandidos Publications

Subject

Cancer Research,Oncology

Cited by 16 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Safety assessment of neurokinin-1 receptor antagonist: real-world adverse event analysis from the FAERS database;Frontiers in Pharmacology;2024-07-31

2. Fosnetupitant for the Prevention of Chemotherapy-Induced Nausea and Vomiting: A Short Review and Clinical Perspective;Advances in Therapy;2023-03-08

3. A phase 3 safety study of fosnetupitant as an antiemetic in patients receiving anthracycline and cyclophosphamide: CONSOLE‐BC;Cancer;2022-01-19

4. Randomized, Double-Blind, Phase III Study of Fosnetupitant Versus Fosaprepitant for Prevention of Highly Emetogenic Chemotherapy-Induced Nausea and Vomiting: CONSOLE;Journal of Clinical Oncology;2022-01-10

5. Efficacy of intravenous NEPA, a fixed NK1/5-HT3 receptor antagonist combination, for the prevention of chemotherapy-induced nausea and vomiting (CINV) during cisplatin- and anthracycline cyclophosphamide (AC)-based chemotherapy: A review of phase 3 studies;Critical Reviews in Oncology/Hematology;2021-01